Page 155 - Biomarkers for risk stratification and guidance in heart failure
P. 155

                                Chapter 7
                        154
Table 1
N Blinding Marker
69 Double NT-proBNP
220 Unknown BNP
499 Single
364 Double NT-proBNP
278
No NT-proBNP
252 Single NT-proBNP
345 Single
130 No BNP
279 No BNP
151 No NT-
407
No NT-proBNP
Single/ multicenter
Single Partially
Multi (17) No
Multi (15)
Single Yes
Multi (8) Yes No
Multi (45) No
Multi (12) Yes Dialysis
Multi (3) Yes
Multi (19)
Multi (18) No
Incl after hospital adm
< 1 yr
Partially
Partially
Exclusion renal dysfunction
Kreat > 200 μmol/l
Kreat > 250 μmol/l
Kreat
Kreat > 250 μmol/l
Kreat > 265 μmol/l
Kreat > 309 μmol/l
Kreat
Kreat
Kreat > 200 μmol/l
(NT-pro)BNP aim, pg /ml
1695 1839-2127 HF score
100 352 UC
400/800* 3998-4657 NYHA
1271
2200
50%  2661-2429 UC
(post) discharge
2x discharge
150/300* 631 - 596 UC
1000
< 30% increase
(NT-pro)BNP BL, pg /ml†
2012 - 1996 -2012
2216 - 2469 - 2359
2961 - 2936
453-440 CS
2344 - 1946
1955 UC
Control aim
UC
70 66 76 76 71 78 72 59 71 63 73
Age Female LVEF, % (incl;BL)
23% <40; 27
42% <45; 30
34% ≤45; 30
36% No; 39
35%
29% <50; 32
43% No; 36
31% ≤35; 20
27% 15% 25%
Isch. HF
ACE/ARB↑† Yes β-block↑† No MRA↑† Yes Diuretics↑† Yes FU, months 9.5
52%
Yes Yes No‡ Yes§ Yes Yes No‡ Yes
? 60% 41% ? 56% 43% No Yes Yes No Yes No NoNoYesNoYes No No No No No Yes No No Yes No No Decrease No
Troughton 200044
STARS-BNP 200746
TIME-CHF 200949
Battle- scarred 200947
Berger 201048
SIGNAL-HF 201052
PRIMA 201051
STARBRITE 201155
UPSTEP 201154
PROTECT 201153
Northstar 201356
74%
58%
72%
64%
NT- proBNP
NT- proBNP
proBNP Single
> 220 μmol/l
> 250 μmol/l
> 221 μmol/l
≤ fc II
IC/UC
IC/UC
UC
? Yes No‡ No
? No No‡ (Decrease)‖ 15 18 24 ≥12; 18
9 ≥15, 24 >3 ≥ 12 ≥6; 10
≥6;30
<40 or CT- ratio
> 0.5; 29
<40; 57% ≤40; 27 ≤45; 30 <30
   153   154   155   156   157